Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsty J Thomson

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Expert Review of Anticancer Therapy|July 9, 2005
Role of allogeneic stem cell transplantation in multiple myelomaKirsty J Thomson, Karl S Peggs
British Journal of Haematology|July 30, 2013
Allogeneic transplantation in the UK: an aggregation of marginal gains?Kirsty J Thomson, Karl S Peggs
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adultsJonathan I Sive, Kirsty J Thomson, Emma C Morris, et al.
British Journal of Haematology|December 17, 2011
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failureSajir G Mohamedbhai, Noha Edwards, Emma C Morris, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
British Journal of Haematology|January 21, 2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposureJaimal Kothari, Karl S Peggs, Antonia Bird, et al.
Transplantation and Cellular Therapy|May 7, 2021
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell TransplantationMaria A V Marzolini, Andrew J Wilson, Emilie Sanchez, et al.
British Journal of Haematology|June 30, 2015
Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin LymphomaSatyen H Gohil, Kirit M Ardeshna, Jonathan M Lambert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphomaKirsty J Thomson, Emma C Morris, Adrian Bloor, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|July 9, 2005
Role of allogeneic stem cell transplantation in multiple myelomaKirsty J Thomson, Karl S Peggs
British Journal of Haematology|July 30, 2013
Allogeneic transplantation in the UK: an aggregation of marginal gains?Kirsty J Thomson, Karl S Peggs
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 21, 2012
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adultsJonathan I Sive, Kirsty J Thomson, Emma C Morris, et al.
British Journal of Haematology|December 17, 2011
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failureSajir G Mohamedbhai, Noha Edwards, Emma C Morris, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
British Journal of Haematology|January 21, 2014
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposureJaimal Kothari, Karl S Peggs, Antonia Bird, et al.
Transplantation and Cellular Therapy|May 7, 2021
Natural History of Epstein-Barr Virus Replication and Viral Load Dynamics after Alemtuzumab-Based Allogeneic Stem Cell TransplantationMaria A V Marzolini, Andrew J Wilson, Emilie Sanchez, et al.
British Journal of Haematology|June 30, 2015
Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin LymphomaSatyen H Gohil, Kirit M Ardeshna, Jonathan M Lambert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphomaKirsty J Thomson, Emma C Morris, Adrian Bloor, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Pageof 3